Results 271 to 280 of about 1,574,312 (309)
Some of the next articles are maybe not open access.
2015 And Human Cancer: Back to Overall Survival
Future Oncology, 201610.2217/fon-2015-0085 © 2016 Future Medicine Ltd At the end of the year, it is time to take stock. What has been the revolutionary innovation in oncology in 2015? Key steps in translational research are certainly strengthening the foundations of cancer knowledge. As genome sequencing has allowed outlining the mutational landscape of several tumor types
Ciccarese C., Massari F., Tortora G.
openaire +3 more sources
FOXP3 Expression and Overall Survival in Breast Cancer
Journal of Clinical Oncology, 2009PurposeThe transcription factor forkhead box P3 (FOXP3) up- or downregulates a large number of genes and has been recently reported to be expressed in tumor cells. We investigated the prognostic importance of FOXP3 expression in patients with breast cancer.Patients and MethodsThe expression patterns of FOXP3 were characterized by immunohistochemistry ...
A. Merlo +7 more
openaire +2 more sources
Overall Survival: Still the Gold Standard
The Cancer Journal, 2009Overall survival (OS) is the gold standard primary end point to evaluate the outcome of any drug, biologic, intervention, or procedure that is assessed in oncologic clinical trials. OS is universally recognized as being unambiguous, unbiased, with a defined end point of paramount clinical relevance, and positive results provide confirmatory evidence ...
James J, Driscoll, Oliver, Rixe
openaire +2 more sources
Intergroup Exemestane Study mature analysis: overall survival data
Anti-Cancer Drugs, 2008The findings of the Intergroup Exemestane Study (IES) challenge the standard adjuvant endocrine therapy consisting of 5 years of tamoxifen therapy in women with oestrogen receptor-positive breast cancer. The IES study confirmed that switching to an aromatase inhibitor (AI) such as exemestane after 2-3 years of tamoxifen therapy resulted in improved ...
openaire +2 more sources
Adjuvant osimertinib improves overall survival
Nature Reviews Clinical Oncology, 2023openaire +2 more sources
Overall Survival vs Disease-Specific Survival—Reply
JAMA Oncology, 2018Sham, Mailankody, Vinay, Prasad
openaire +2 more sources
Second-line axi-cel improves overall survival
Nature Reviews Clinical Oncology, 2023openaire +2 more sources